Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Tourette Syndrome Treatment Market

Tourette Syndrome Treatment Market Share

Report ID: GMI10872
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Tourette Syndrome Treatment Market Share

The treatment market for Tourette syndrome is being reshaped by relentless innovation and technological progress. Major players in the market are not only providing a broad spectrum of advanced treatments, from medications to various therapies, but are also tailoring these solutions to meet the distinct needs of each patient. To stay competitive and protect their market position, these companies are prioritizing strategic moves. Central to these strategies is a significant commitment to research and development (R&D). Through these R&D investments, companies aim to roll out new products and refine their current offerings, thus propelling the transformation of the Tourette syndrome treatment arena.

Tourette Syndrome Treatment Market Companies

Prominent players operating in the Tourette syndrome treatment industry include:

Service Providers
- Boston Children's Hospital
- Mayo Clinic
- Stony Brook Medicine
- Massachusetts General Hospital
- UPMC Children's Hospital of Pittsburgh
Medication Manufacturers
- AstraZeneca PLC
- Bausch Health Companies Inc.
- Catalyst Pharmaceuticals, Inc.
- Eli Lilly and Company
- Emalex Biosciences, Inc.
- Novartis AG
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

In 2023, the Tourette syndrome treatment industry was valued at USD 2.4 billion and is projected to grow at a CAGR of 4.8% from 2024 to 2032. The market's growth is primarily fueled by the rising incidence of Tourette syndrome, a trend largely linked to enhanced diagnostic capabilities and increased awareness.

In 2023, motor tics segment commanded a dominant market share of 63.5%, owing to widespread occurrence of motor tics in TS patients, coupled with the need for a diverse range of specialized treatments aimed at alleviating symptoms and enhancing the quality of life.

By 2032, North American Tourette syndrome treatment industry is projected to reach USD 1.5 billion, growing at a CAGR of 5%, due to its advanced healthcare infrastructure and ongoing neurological disorder research.

Some notable medicine manufacturers include AstraZeneca PLC, Bausch Health Companies Inc., Catalyst Pharmaceuticals, Inc., Eli Lilly and Company, Emalex Biosciences, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., and Sun Pharmaceutical Industries Limited among others.